`From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`**External Message**
`
`Brian,
`
`Brett Davis <Brett.Davis@tnw.com>
`Wednesday, August 3, 2022 5:07 PM
`Lemon, Brian; Joyce, Alexandra; Belt, Erik Paul; Sterlin, Ian; Curran, John
`Mark Bettilyon; Peter deJonge; Jed Hansen; francis.digiovanni@faegredrinker.com;
`thatcher.rahmeier@faegredrinker.com; Kaelynn Moultrie
`Novarad v. Medivis
`
`Pursuant to Paragraph 14 of the Scheduling Order regarding claim construction issue identification, Novarad asserts that
`all of the claim terms in the asserted patents should be given their plain and ordinary meaning as understood by one
`having ordinary skill in the art. Therefore, no court claim construction is necessary.
`
`Brett
`
`___________________________________
`
`Brett J. Davis • Registered Patent Attorney
`Thorpe North & Western | 801.566.6633 | tnw.com
`
`CONFIDENTIALITY NOTICE: This communication, and any documents, files or previous email messages attached to it, may contain confidential information that is legally privileged. Do not
`read this email if you are not the intended recipient. If you are not the intended recipient, or a person responsible for delivering it to the intended recipient, you are hereby notified that any
`disclosure, copying, distribution or use of any of the information contained in or attached to this transmission is strictly prohibited. If you have received this transmission in error, please
`immediately notify us by email, forwarding this to the email address above or by telephone at (801) 566-6633, and destroy the original transmission and its attachments without reading or
`saving in any manner. Thank you.
`
`1
`
`Medivis Exhibit 1014
`
`1
`
`